TACSTD2 and female reproductive organ cancer: All TROP2-directed ADCs currently either FDA approved (i.e., sacituzumab govitecan and datopotamab deruxtecan) or in Phase II/III clinical trials (i.e., sacituzumab tirumotecan and datopotamab deruxtecan) against gynecologic cancers, and the anti-HER2 ADC fam-trastuzumab-deruxtecan, share a similar toxic payload (i.e., a topoisomerase inhibitor).